Over a median follow-up period of 4.0 years, the overall incidence of cancers (excluding non-melanoma skin cancer (NMSC)) was greater in patients receiving combined doses of tofacitinib (4.2%; 122 cases) compared to those treated with a TNF inhibitor (2.9%; 42 cases) [31]. The gene discussed is TNF; the disease is cancer.